内容来源：https://www.geekwire.com/2026/etzioni-on-ai-the-virgin-unicorns/

内容总结：

十二家AI实验室估值超福特通用，却无一产品上市——“处女独角兽”现象引发市场热议

当前，人工智能领域出现了一组奇特的公司群体：12家AI实验室的合计估值已超过福特和通用汽车两大传统车企的总市值，然而，这些公司目前没有任何一款产品在售，甚至尚未产生任何收入。有分析人士将这类企业称为“处女独角兽”——估值超过十亿美元，却尚无产品或营收“破处”。

估值与现实的巨大反差

数据显示，这12家AI实验室已累计融资超过290亿美元，总估值逼近1300亿美元。然而，它们尚未向客户交付任何一件可购买的商品。以具体公司为例：“普罗米修斯计划”估值380亿美元，已融资162亿美元，但产品栏为“无”；“安全超级智能”估值320亿美元，融资30亿美元，同样无产品；“思考机器实验室”估值120亿美元，融资20亿美元，仅有一款面向研究者的微调工具“Tinker”处于有限研究发布阶段……整份名单中，没有任何一家公司拥有面向大众的商业化产品。

追问：谁在做局？逻辑何在？

面对这一现象，两个核心问题值得深究：第一，为何老练的投资者会向尚未成型的“准公司”开出成长型支票？第二，历史经验告诉我们将迎来怎样的结局？

通过对这12家企业的深度剖析，可以归纳出四大模式：

1. “血统溢价”：每家公司的创始人均为各自领域的公认领袖，且高度集中于少数顶尖机构。约五分之四的创始人拥有博士学位，大多来自伯克利、斯坦福、麻省理工、多伦多大学等名校。在从业背景上，DeepMind和OpenAI的校友几乎主导了这份名单。投资者实质上是在为简历定价，而非产品。

2. “英伟达造王者”：12家公司中有9家获得了英伟达的投资。这家“卖铲人”同时化身为“矿主”，不仅通过销售算力获利，更以股权投资方式锁定了早期参与AI最前沿赌局的机会。

3. 融资结构异常“宽”：每轮融资通常由10到20家机构组成的财团参与，不仅包括传统风投，更引入了摩根大通、贝莱德、主权财富基金、甚至贝索斯个人等“资产负债表资本”，结构上已完全不同于经典的风投模式。

4. “后大语言模型”叙事：每家公司都在论证同一个核心观点：当前范式（仅靠扩大大语言模型）无法抵达通用人工智能，需要新的路径（如世界模型、强化学习、智能体系统等）。在这里，“论文就是产品，产品就是承诺”。

市场争议：是彩票，还是下一座金矿？

对于这种“无产品、高估值”的现象，市场已发出谨慎声音。橡树资本霍华德·马克斯在2025年12月的备忘录中将其描述为“彩票思维”，即投资者在极大概率失败的情况下，押注于巨大的回报。有媒体报道称，在一次“思考机器实验室”的融资路演中，创始人米拉·穆拉蒂甚至无法回答关于“正在建造什么”的问题。

然而，投资者并非盲目。OpenAI的案例提供了最有力的支撑：从2015年成立到2022年底ChatGPT发布，OpenAI在长达7年的时间里同样处于无消费者产品的“处女独角兽”状态，但随后其营收在三年内从零飙升至超100亿美元。红杉资本等顶级投资机构如今押注的，正是“OpenAI第二”的可能性。

历史镜鉴：更像生物科技，而非互联网泡沫

分析人士指出，当前情况与2000年的互联网泡沫有本质区别。Webvan、Pets.com等失败是因为产品与商业模式不符，而并非“无产品”。真正的警示案例来自过去15年的“明星创始人空壳项目”：Magic Leap融资35亿美元后产品失败；Quibi融资17.5亿美元仅存活6个月；Inflection AI融资15亿美元后被微软“吞并”。

从结构上看，这些AI实验室更像生物科技公司：无营收、科学驱动、周期长达十年、结果高度二元化、退出路径通常是被收购。然而，两者的融资逻辑截然相反——生物科技投资者按科学里程碑分阶段放款，并为失败做好准备；而“处女独角兽”的投资者则基于一份简历一次性注资，且定价基于成功。

潜在结局：巨大的赌局

以12家公司合计1270亿美元的估值计算，要实现早期风投通常追求的10倍回报，其中唯一的赢家必须创造出约1.3万亿美元的价值。历史告诉我们，泡沫中偶尔也会诞生亚马逊或谷歌这样的巨头。但问题在于：在12家尚无产品的实验室里，谁能成为那个价值“千倍独角兽”？这或许是当前AI投资领域最昂贵也最悬而未决的问题。

中文翻译：

12家AI实验室的总估值超过了福特和通用汽车的总和，但没有一家在销售任何产品。我将它们称为“处子独角兽”——估值超过十亿美元，却没有任何产品或收入。
OpenAI证明，一家拥有正确产品的AI研究实验室可以成为地球上最具价值的公司之一。其他十几家AI实验室正试图复制这一奇迹。它们已筹集超过290亿美元，总估值接近1300亿美元，却未交付任何可供客户购买的产品。
有两个问题值得思考：

• 为什么精明的投资者会给“预公司”开出成长阶段的支票？
• 历史对此类故事的结局有何启示？

顶尖处子独角兽

为解答这些问题，我们需识别这批公司中的四种模式。

模式一：血统溢价。 每位创始人都是其领域公认的领军人物，且多数来自少数几个机构。约五分之四拥有博士学位，主要来自伯克利、斯坦福、麻省理工、多伦多大学、阿尔伯塔大学、剑桥大学、伦敦大学学院等少数高校的计算机科学专业；其余多数则从这些项目退学创业。
在雇主方面，集中度更高。12家公司中，4家由DeepMind校友主导（Ineffable、Reflection、Ricursive、Recursive Superintelligence），2家由OpenAI校友主导（Thinking Machines、Safe Superintelligence）。AMI Labs源自Meta的FAIR团队，Humans&的创始人则来自Anthropic、xAI和谷歌。斯坦福和伯克利的教职员工占据了其余多数（World Labs、Physical Intelligence，以及Humans&的诺亚·古德曼）。
DeepMind、OpenAI、伯克利和斯坦福这四家机构，几乎产出了上表中所有“处子独角兽”的创始人。投资者定价的是简历，而非产品。

模式二：英伟达为“造王者”。 表中12家公司中，9家有英伟达作为投资者。这位“卖铲人”同时也是“淘金者”的股东。英伟达能早期洞察最具雄心的AI赌注，锁定算力承诺，并以近乎零边际成本获得投入资本的数倍回报。卖铲子本已是好生意，连矿山也一并占有则史无前例。

模式三：股权结构异常宽泛。 表中每轮融资都包含由10至20家投资者组成的联合体——包括风投机构、企业战略投资者、主权财富基金和个人。红杉和a16z依然领投，但融资规模之大，需借助摩根大通、贝莱德、Alphabet、英国主权AI基金、三星、淡马锡、阿布扎比投资局（ADIA）及贝索斯本人等机构的资产负债表资本来填补。这使得这些轮次在结构上不同于经典的风险融资。

模式四：后LLM理论。 每家公司都以某种形式论证当前范式不够——即扩展大型语言模型无法达到通用人工智能（AGI），需要其他方法（世界模型、强化学习、智能体系统、AI科学家、新型芯片、形式化数学推理）。理论即是产品，产品则是一个承诺。

其他人对这些独角兽的剖析：

• 霍华德·马克斯在其2025年12月的橡树资本备忘录《这是泡沫吗？》中，将投资者行为描述为“彩票思维”——投资者支持没有产品的初创公司，寄望于巨大回报的梦想，尽管失败概率极高。
• 德里克·汤普森在10月的文章中阐述了同样情况：一位投资者将Thinking Machines的推销会描述为“最荒谬的推销会”，因为米拉·穆拉蒂“无法回答任何关于她正在构建什么的问题”。
• GeekWire的年度风投投资者调查也发现类似 skepticism 更近在咫尺：泡沫在早期阶段最为明显，AI叙事可以替代真实 traction。

“彩票”的框架如今已成共识。但这场彩票会兑现吗？评估几率的一种方法是回顾历史。

历史的教训
最接近的历史类比并非互联网泡沫时代。Webvan、Pets.com和Boo.com的失败并非因为它们是“预产品”公司，而是因为它们有产品但商业模式糟糕。这些公司将资本消耗在基础设施和营销上，而非研发。
更贴切的警示案例是过去15年间以明星创始人、“预产品”为特征的失败：

• Magic Leap凭借罗尼·阿博维茨之前的成功退出，9年内筹集35亿美元，最终推出了一款失败产品。
• Quibi凭借卡岑伯格和惠特曼的声望筹集17.5亿美元，仅存活6个月。
• Inflection AI凭借穆斯塔法·苏莱曼和里德·霍夫曼筹集15亿美元，于2024年实质上被微软吸收——团队被雇佣、技术被授权、公司沦为空壳。
  在上述每个案例中，创始人资历带来了资金，但产品从未支撑起估值。

然而，结构上最接近的类比是生物科技。2021年生物科技IPO中约80%是零收入公司。临床前药物上市的概率低于10%，研发耗时十年，成本达10亿美元。但本特利大学一项针对1997年至2016年319家生物科技IPO的研究发现，尽管失败率超过50%，该群体仍创造了超过1000亿美元的净股东价值。赢家的规模足以覆盖整个投资组合。许多最成功的生物科技公司在盈利前就被收购了。

“处子独角兽”是生物科技形态的企业：零收入、科学驱动、十年周期、二元结果、收购为常见退出方式。但它们并非按生物科技模式融资。生物科技投资者以里程碑形式、按科学成果分阶段释放资本，并预期大多数候选项目会失败。而“处子独角兽”的投资者则凭一份简历，以一轮大规模融资释放资本，并定价于成功。业务形态相同，融资逻辑却截然相反。这种错配正是失望的来源。

为何红杉仍投资
OpenAI的故事对生物科技类比构成了挑战。从2015年创立到2022年底ChatGPT发布，OpenAI完完全全像一只“处子独角兽”——七年没有面向消费者的产品，数十亿资本，只有研究成果。随后ChatGPT推出，收入在三年内从零飙升至超过100亿美元。没有任何生物科技公司曾如此快速扩张。
红杉及其他向当今“处子独角兽”开出支票的投资者，并非在按生物科技的结果定价。他们是在为第二个OpenAI的出现定价。
上表清晰显示了这一赌注的规模。早期风投投资者追求10倍回报。这12家公司中多数将归于零，因此唯一的赢家必须独自撑起其余11家。以1270亿美元的累计估值计算，这意味着赢家需创造约1.3万亿美元的价值。
这不是预测——而是风投已押下的赌注。红杉和a16z曾对OpenAI和Anthropic下过完全相同的赌注，账面回报已多次证实其正确性。Anthropic自身在2022年看起来就像一只“处子独角兽”——然后它推出了Claude并建立了收入。
历史记录暗示着某种 skepticism。但泡沫总有办法在一片狼藉中催生出偶尔的亚马逊或谷歌。识别哪只“处子独角兽”将成为万亿美元公司——“千角兽”，即一千只独角兽于一身——是困难的。你会押注哪一家？

英文来源：

Twelve AI labs have a combined valuation larger than Ford and GM. None of them sell anything. I call them the Virgin Unicorns — valued above a billion dollars, but innocent of product or revenue.
OpenAI proved that an AI research lab with the right product could become one of the most valuable companies on earth. A dozen other AI labs are trying to repeat the trick. They have raised more than $29 billion at a combined valuation approaching $130 billion, without shipping anything a customer can buy.
Two questions are worth asking:

• Why are sophisticated investors writing growth-stage checks to pre-companies?

• What does history say about how this story ends? Top Virgin Unicorns	Company	Founded	Founders	Valuation	Raised	Lead Investors	Product
  Project Prometheus	2025	Bezos, Bajaj	$38B	$16.2B	JPMorgan, BlackRock, Bezos	None
  Safe Superintelligence	2024	Sutskever, Gross, Levy	$32B	$3B	Greenoaks, Sequoia, a16z, Lightspeed, DST, Alphabet, Nvidia	None
  Thinking Machines Lab	2025	Murati, Schulman, Zoph, Weng	$12B	$2B	a16z, Nvidia, AMD, Cisco, Accel, Jane Street	Tinker*
  Reflection AI	2024	Laskin, Antonoglou	$8B	$2.1B	Nvidia, Lightspeed, Sequoia, Schmidt, Citi, 1789 Capital	None
  Physical Intelligence	2024	Levine, Finn, Hausman, Ichter, Groom	$5.6B	$1B+	CapitalG, Lux, Thrive, Bezos, T. Rowe Price, Index	Demo
  Ineffable Intelligence	2025	Silver, Czarnecki, Espeholt, Oh	$5.1B	$1.1B	Sequoia, Lightspeed, Nvidia, Google, UK Sovereign AI, Index	None
  World Labs	2024	Li, Johnson, Mildenhall	$5B	$1.2B	a16z, NEA, Radical, Nvidia, AMD, Autodesk, Emerson Collective	Marble*
  Recursive Superintelligence	2025	Socher, Rocktäschel, Tian, Clune, Tobin	$4.65B	$650M	GV, Greycroft, Nvidia, AMD	None
  Unconventional AI	2025	Rao, Carbin, Achour, Lee	$4.5B	$475M	a16z, Lightspeed, Sequoia, Lux, DCVC, Bezos	None
  Humans&	2025	Zelikman, Harik, Peng, He, Goodman, and others	$4.48B	$480M	SV Angel, Harik, Nvidia, Bezos, GV, Emerson Collective	None
  Ricursive Intelligence	2025	Goldie, Mirhoseini	$4B	$335M	Lightspeed, Sequoia, DST, Nvidia, Felicis, Radical	None
  AMI Labs	2025	LeCun, LeBrun	$3.5B	$1.03B	Cathay, Greycroft, Hiro, HV, Bezos Expeditions, Nvidia, Samsung, Temasek	None
  Total	~$127B	~$30B
  * Limited research release. Tinker is a fine-tuning tool for researchers; Marble is a 3D-world-generation API in early partner access. Neither is a general-availability commercial product. Sources: company announcements, Bloomberg, Financial Times, TechCrunch, Crunchbase, and PitchBook reporting from 2024-2026. Valuations reflect the most recent confirmed round; figures for rounds in active negotiation are not included.

  To answer these questions, let’s identify four patterns across this cohort of companies.
  Pattern 1: The pedigree premium. Every founder is a recognized leader in their field, and most come from a small set of institutions. Roughly four-fifths hold PhDs, mostly in computer science from a handful of universities — Berkeley, Stanford, MIT, Toronto, Alberta, Cambridge, UCL — and most of the rest left PhDs at one of those programs to start their companies.
  On the employer side, the concentration is tighter still. Four of the twelve companies are anchored by DeepMind alumni (Ineffable, Reflection, Ricursive, Recursive Superintelligence). Two are anchored by OpenAI alumni (Thinking Machines, Safe Superintelligence). AMI Labs traces back to Meta’s FAIR group, and Humans& draws its founders from across Anthropic, xAI, and Google. Stanford and Berkeley faculty appointments account for most of the rest (World Labs, Physical Intelligence, and Noah Goodman of Humans&).
  Four institutions — DeepMind, OpenAI, Berkeley, and Stanford — have produced the founders of nearly every Virgin Unicorn in the table. Investors are pricing CVs, not products.
  Pattern 2: Nvidia as kingmaker. Nine of the twelve companies in the table have Nvidia as an investor. The supplier of the picks and shovels is also an equity holder in the prospectors. Nvidia gets early visibility into the most ambitious AI bets, locks in compute commitments, and earns multiples on capital deployed at near-zero marginal cost. Selling the shovels was already a good business. Owning the mines too is unprecedented.
  Pattern 3: The cap tables are unusually wide. Each round in the table includes a syndicate of ten to twenty investors — venture firms, corporate strategics, sovereign wealth funds, and individuals. Sequoia and a16z still lead. But the rounds are large enough that they require balance-sheet capital — from JPMorgan, BlackRock, Alphabet, the UK Sovereign AI Fund, Samsung, Temasek, ADIA, and Bezos personally — to fill out. That makes these rounds structurally different from classical venture financings.
  Pattern 4: A post-LLM thesis. Every company is arguing, in some form, that the current paradigm isn’t enough — that scaling LLMs won’t reach AGI, and that something else (world models, reinforcement learning, agentic systems, AI scientists, novel chips, formal mathematical reasoning) is required. The thesis is the product. The product is a promise.
  Others have dissected these unicorns:

• Howard Marks, in his December 2025 Oaktree memo Is It a Bubble?, described investor behavior as “lottery-ticket thinking” — investors backing startups with no product on the dream of an enormous payoff despite an overwhelming probability of failing.
• Derek Thompson, writing in October, framed the same dynamic by reporting that a Thinking Machines pitch meeting was described by one investor as “the most absurd pitch meeting” because Mira Murati “couldn’t answer any questions” about what she was building.
• GeekWire’s own year-end survey of regional venture investors found the same skepticism closer to home: the bubble, they said, is most pronounced at the early stages, where AI storytelling can substitute for real traction.
  The lottery-ticket framing is now conventional wisdom. But will this lottery pay out? One way to handicap the odds is to look to the past.
  What history teaches us
  The closest historical parallel is not the dot-com era. Webvan, Pets.com, and Boo.com failed not because they were pre-product, but because they had products and bad business models. Those companies burned capital on infrastructure and marketing, not on research.
  The closer cautionary tales are the celebrity-founder pre-product flops of the last fifteen years.
• Magic Leap raised $3.5 billion over nine years on the strength of Rony Abovitz’s prior exit and shipped a flop.
• Quibi raised $1.75 billion on Katzenberg and Whitman’s pedigree and lasted six months.
• Inflection AI raised $1.5 billion on Mustafa Suleyman and Reid Hoffman and was effectively absorbed into Microsoft in 2024 — its team hired, its technology licensed, its company hollowed into a shell.
  In each case, founder credentials raised the money. The product never justified the valuation.
  The structurally closest analogy, though, is biotech. Roughly 80% of 2021 biotech IPOs were pre-revenue. The probability that a pre-clinical drug reaches commercialization is under 10%. Development takes a decade and costs $1 billion. Yet a Bentley University study of 319 biotech IPOs from 1997 to 2016 found that the cohort produced over $100 billion in net shareholder value despite a failure rate above 50%. The winners were large enough to carry the portfolio. And many of the most successful biotechs were acquired before reaching profitability.
  The Virgin Unicorns are biotech-shaped businesses. Pre-revenue, science-driven, decade-long timelines, binary outcomes, acquisition as the usual exit. But they aren’t financed like biotechs. Biotech investors release capital in milestone tranches tied to specific scientific results, and they expect most candidates to fail. Virgin Unicorn investors release capital in one large round on the strength of a CV, and price for success. Same shape of business, opposite financing logic. That mismatch is where the disappointment will come from.
  Why Sequoia invests anyway
  The OpenAI story counters the biotech analogy. From its 2015 founding to the ChatGPT launch in late 2022, OpenAI looked exactly like a Virgin Unicorn — pre-consumer-product for seven years, billions in capital, and only research to show for it. Then ChatGPT shipped and revenue went from zero to over $10 billion in three years. No biotech has ever scaled like that.
  Sequoia and other investors writing checks to today’s Virgin Unicorns aren’t pricing for biotech outcomes. They’re pricing for the second coming of OpenAI.
  The table above makes the size of that bet legible. Early-stage venture investors aim for a 10x return. Most of these twelve will return zero, so the one winner has to carry the other eleven by itself. At a $127 billion aggregate marked-up value, that means the winner alone has to produce something like $1.3 trillion in value.
  That is not a forecast — it is the bet the VCs have already placed. Sequoia and a16z made exactly this kind of bet on OpenAI and Anthropic, and the on-paper returns have already vindicated it many times over. Anthropic itself looked like a Virgin Unicorn in 2022 — and then it shipped Claude and built revenue.
  The historical record suggests some skepticism. But bubbles have a way of producing the occasional Amazon or Google amid the wreckage. Identifying which Virgin Unicorn will become a trillion-dollar company — a “kilocorn,” a thousand unicorns in one — is tough. Which one would you bet on?